Resistance to cancer therapies has been a commonly observed phenomenon in clinical
practice, which is one of the major causes of treatment failure and poor patient survival. The …

High-grade gliomas (World Health Organization grades III and IV) are the most frequent and
fatal brain tumors, with median overall survivals of 24–72 and 14–16 months, respectively …

The lack of reliable predictive biomarkers to guide effective therapy is a major obstacle to the
advancement of therapy for high-grade gliomas, particularly glioblastoma (GBM), one of the …

Background Resistance to temozolomide (TMZ) is a major obstacle to preventing
glioblastoma (GBM) recurrence after surgery. Although long noncoding RNAs (lncRNAs) …

The prognosis for diffusely infiltrating gliomas at World Health Organization (WHO) grade 2–
4 remains dismal due to their heterogeneity. The rapid development of genome-wide …

Simple Summary Diffuse gliomas are a type of brain tumour afflicting adults and children,
often with a fatal outcome. An accurate diagnosis is required to give patients correct …

Glioblastoma (GBM), the most lethal type of brain tumor in adults, has considerable cellular
heterogeneity. The standard adjuvant chemotherapeutic agent for GBM, temozolomide …

Abstract Background O 6-methylguanine-DNA-methyltransferase (MGMT) methylation status
does not correlate with temozolomide (TMZ) sensitivity in all IDH-wildtype glioblastoma …

Simple Summary The standard of care for patients with primary glioblastoma multiforme
consists of neurosurgery, radiochemotherapy, and maintenance chemotherapy. We added …

High grade gliomas are the most common primary aggressive brain tumours with a very
poor prognosis and a median survival of less than 2 years. The standard management …